Skip to main content
. 2020 Sep 18;12:1758835920958354. doi: 10.1177/1758835920958354

Figure 6.

Figure 6.

TNBC cell line sensitivity to DDR small molecule inhibitors. (A) Cells continuously exposed to ATM inhibitor KU-55933 (ATMi). (B) Cells continuously exposed to ATR inhibitor AZD6738 (ATRi). (C) Cells continuously exposed to CHK1/2 inhibitor prexasertib (LY2606368). (D) Cells continuously exposed to DNA-PK inhibitor NU7062. (E) IC50 values for DDR inhibitors.

DDR, DNA damage response; TNBC, triple negative breast cancer.